Related Experiment Video
Updated: Aug 28, 2025

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
Published on: August 17, 2022
Approach to Lymphoma-Associated Cardiomyopathy
Mohamed Riad Abdelgawad Abouzid1, Maha Hameed2, Maanya Rajasree Katta3
1From the Baptist Hospitals of Southeast Texas, Beaumont, TX.
Lymphoma survivors face cardiomyopathy risk from treatments like anthracyclines and radiation. Early collaboration between oncologists and cardiologists is crucial for risk stratification and management of heart conditions.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Cardiomyopathy is a significant complication following lymphoma treatment (Hodgkin's and Non-Hodgkin's).
- It leads to heart failure, arrhythmia, and sudden cardiac death in cancer survivors.
- Anthracyclines and radiation therapy are key culprits in lymphoma-associated cardiomyopathy.
Conclusions:
- Cardiotoxicity is a serious concern in lymphoma survivors.
- A collaborative approach between oncologists and cardiologists is essential for risk assessment and personalized treatment planning.
- Proactive management and surveillance are key to mitigating cardiomyopathy risk.
More Related Videos
09:16Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
Published on: February 28, 2018
13:42Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
Published on: March 8, 2013
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy VI: Nursing Management